No qualifying author-owned investment thesis was confirmed in this post.
no investment thesis
Score1
Comments1
▶ Full Post Text
# Obesity Drug Bets Get a Reality Check—but Investors Shouldn’t Panic.
The obesity-drug trade hit a speed bump. Still, there are reasons investors might want to sit tight.
Novo Nordisk [pre-announced weaker-than-expected guidance](https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026/card/novo-nordisk-stock-dives-on-forecast-for-2026-sales-drop-vCx9y4aptmGOjsgfFCiC), forecasting a 5% to 13% decline in constant-currency sales this year, citing pricing pressure and intensifying competition.
Earlier Tuesday, Pfizer [reported underwhelming data](https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026/card/pfizer-stock-drops-on-obesity-drug-study-data-kSCGz35zBDkrnRG4jMrY) for its once-monthly obesity injection, raising fresh doubts about [the Metsera acquisition](https://www.wsj.com/health/pharma/pfizer-and-metsera-reach-deal-worth-up-to-10-billion-be5def52) it announced last year, and whether it will be enough to support a blockbuster competitor to the Lilly and Novo injections.
The news rattled investors. Pfizer shares fell 3.2%, while Novo Nordisk’s American depositary receipts plunged 15%. Eli Lilly, which is set to report results on Wednesday, slid 3.7%. Altogether, more than $70 billion in market value was wiped out.
But the setbacks might not be as damaging as they first appear. At Novo, much of the pressure stems from pricing concessions taking effect faster than volume gains. Prices have come down quickly, partly as a result of [deals with the Trump administration](https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/eli-lilly-novo-nordisk-cut-weight-loss-drug-prices-in-deal-with-trump-administration-T6sL0JKbt8aIJZSFUQeC?gaa_at=eafs&gaa_n=AWEtsqdEMvFOWpCFIMpfk28d5qN9TmqeaJN7mc50z7KmXOSXVMvppfjUyCJ0ThAfFW0%3D&gaa_ts=6982355e&gaa_sig=uR1RxQUJgayE8wmYU5VsDOOLUnMBYT6zgMN4wLagUDqDgpX8DrS7kc4CxWVRNKTpKYt5PwxDzlezOIzl5KnJig%3D%3D). Reimbursement-driven demand—especially from government programs such as Medicare—is likely to build more slowly. This was a dynamic investors were already bracing for, though the extent of it was surprising.
There are also early reasons for optimism. Novo disclosed that prescriptions for its Wegovy pill had reached about 50,000 a week as of late January, a solid start that suggests the company’s guidance could ultimately prove conservative if uptake continues to build.
Pfizer’s situation is different. It is trying to prove it can carve out its own lane in the obesity market. While the results it released—showing patients lost as much as 12.3% of their body weight versus placebo after 28 weeks—fell short of the efficacy and side-effect profile of Lilly’s weekly injection Zepbound, the drug might only need to be good enough, not better. Its key point of differentiation is dosing: a once-monthly injection.
“We do clearly believe that a well-tolerated monthly injection can be very productive and successful in the marketplace,” Pfizer Chief Financial Officer Dave Denton said in an interview.
Investors in obesity stocks might want to take a breath before running for the exits.
[](https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-02-03-2026?mod=lc_navigation)